ClinicalTrials.gg
RecruitingNCT03243175A3ICHUpdated Apr 7, 2026

Avoiding Anticoagulation After IntraCerebral Haemorrhage

A Phase 3 interventional study of Apixaban 5 MG and left atrial appendage closure in Intracerebral Hemorrhage, Atrial Fibrillation and Microhaemorrhage, sponsored by University Hospital, Lille. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by University Hospital, Lille · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.

Planned enrollment
7th of 13
300 · median 300
Started
2019
with 1 other
Phase 3
5 of 24
2 open now
Primary completion
2029-01
later than 6 of 10 live
Registered
9th of 24
by date
Lead sponsor
4 of 24
University Hospital, Lille

Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 3, reaches primary completion later than 6 of the 10 other live ones, and was the 9th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cerebral Hemorrhage with a site in France, or all of them as a file.
02

Study summary

Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage.

Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.

Read the detailed description

Open label randomised controlled multicentre clinical trial with masked outcome assessment (PROBE design) comparing 3 strategies (1:1:1): anticoagulation with a Direct OAC (Apixaban 5mgx2/day) vs avoid anticoagulation with left atrial appendage closure (LAAC) compared to usual care (avoid anticoagulation).

Primary outcome: the net clinical benefit (composite outcome of major ischaemic and haemorrhagic events) during a follow-up of 24 months (adjudication committee masked to the randomisation arm

The results of A3ICH will help the clinician to decide which strategy is the most effective in terms of benefit/risk ratio to prevent the risk of stroke or systemic embolism in patients with a history of ICH and AF. A3ICH will address this increasingly common dilemma and could affect clinical practice.

Data from A3ICH will contribute to an international individual patient data meta-analysis.

03

Conditions studied

  • Intracerebral Hemorrhage
  • Atrial Fibrillation
  • Microhaemorrhage

Keywords

  • intracerebral hemorrhage
  • atrial fibrillation
  • microhemorrhage
  • oral anticoagulation
  • left atrial appendage closure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria

  • Adult (older than 18 years old, no upper age limit)
  • with a history of paroxysmal, persistent or long-standing non-valvular atrial fibrillation (documented on an )
  • and a CHA2DS2VASc score of 2 or more who have an indication for long-term anticoagulation
  • who suffered from a spontaneous intracerebral haemorrhage (while being treated with oral anticoagulants or not) documented with brain CT or MRI
  • more than 14 days before randomization (no upper delay limit)
  • for whom there is a clinical equipoise regarding the choice of the best preventive strategy to avoid future vascular events.

Exclusion criteria for all treatment groups

  • Pre-randomisation modified Rankin score of 4 or 5
  • Conditions other than atrial fibrillation for which the patient requires long term anticoagulation (for example prosthetic mechanical heart valve)
  • Serious bleeding events within the 6 months before randomisation (except for intracerebral haemorrhage)
  • of less than 1 year
  • Pregnancy or breastfeeding

Exclusion criteria related to the LAAC only

  • due to local, anatomical reasons (such as thrombus in the left atrial appendage, infection with a risk of endocarditis)
  • Patients older than 85 years
  • CHA2DS2VASc score of 2 or 3
  • Patient or attending physician are unwilling to undergo/perform intervention for LAAC

Exclusion criteria related to the Direct OAC only

  • Chronic renal insufficiency (clearance of creatinine by Cockcroft method \< 30ml/min)
  • Body weight lower than 50 kg
  • Allergy to apixaban
  • Coexisting conditions predisposing to head trauma (e.g. gait disturbances, uncontrolled seizures disorders)
  • Patient or attending physician are unwilling to use of Direct OAC
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Direct Oral Anticoagulant (DOAC)

    Apixaban 5MG twice daily

    Drug: Apixaban 5 MG

  • Experimental
    Left Atrial Appendage Closure (LAAC)

    Devices will be chosen by local teams.

    Device: left atrial appendage closure

  • No intervention
    Control

    avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug

Interventions

  • DrugApixabanStudies of ApixabanApixaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apixaban 5mg x 2 during 24 months

    Also known as: ELIQUIS 5mg

  • Deviceleft atrial appendage closure

    left atrial appendage closure

06

What researchers measure

Primary outcomes

  1. Composite of all fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events

    The composite endpoint will enable to evaluate the net clinical benefit of the different therapeutic strategies. Definition of fatal event: when death is occurring within 30 days after the events.

    Time frame: within 24 months after randomization.

Secondary outcomes

  1. Each individual component of the composite outcome (fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events).

    fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events).

    Time frame: at 12 and 24 months after randomization

  2. Death of any cause

    death

    Time frame: at 12 and 24 months after randomization

  3. Modified Rankin Scale

    functional dependence

    Time frame: at 12 and 24 months after randomization

  4. EQ-5D (EuroQoL) Score

    health-related quality of life

    Time frame: at 12 and 24 months after randomization

  5. neuroradiological biomarkers

    on brain MRI

    Time frame: Baseline

  6. Complications of endovascular treatment

    including device related complications

    Time frame: up to 30 days

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Cochrane A, Chen C, Stephen J, Ronning OM, Anderson CS, Hankey GJ, Al-Shahi Salman R. Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD012144. doi: 10.1002/14651858.CD012144.pub3. PubMed 36700520 ↗
  • Li L, Poon MTC, Samarasekera NE, Perry LA, Moullaali TJ, Rodrigues MA, Loan JJM, Stephen J, Lerpiniere C, Tuna MA, Gutnikov SA, Kuker W, Silver LE, Al-Shahi Salman R, Rothwell PM. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurol. 2021 Jun;20(6):437-447. doi: 10.1016/S1474-4422(21)00075-2. PubMed 34022170 ↗

Individual participant data

Plan to share: Yes — Prof Cordonnier (chief investigator of A3ICH) is a member of the international Collaboration Of Controlled Randomised trials of Oral Antithrombotic drugs after intraCranial Haemorrhage (COCROACH - coordination Prof Rustam Al-Shahi Salman, UK) working towards a pre-planned individual patient data meta-analysis

Supporting information: Study protocol, Informed consent form, Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for Jan 2029, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2017
First posted
Aug 8, 2017
StartActual
Jan 17, 2019
Primary completionEst.
Jan 2029
CompletionEst.
Dec 2029
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03243175
Responsible party
Sponsor
First posted
Aug 8, 2017
Start date
Jan 17, 2019
Primary completion
Jan 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Apr 7, 2026

Study contacts

Charlotte Cordonnier, MD, PhD
Contact
charlotte.cordonnier@chru-lille.fr
3 20 44 68 14 ext. +33
Charlotte Cordonnier, MD, PhD
principal investigator · University Hospital Lille, Inserm, Univ Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion